

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau**AB**

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : G01N 33/543, 33/53, A61K 37/02 A61K 39/00	A1	(11) International Publication Number: WO 92/09893 (43) International Publication Date: 11 June 1992 (11.06.92)
(21) International Application Number: PCT/US91/08654 (22) International Filing Date: 25 November 1991 (25.11.91) (30) Priority data: 619,525 29 November 1990 (29.11.90) US (71)(72) Applicant and Inventor: CARBAUGH, John, E. [US/ US]; 1701 Pennsylvania Avenue N.W., Washington, DC 20006 (US). (72) Inventor: CHIKNAS, Steven, G. ; 111 Wolfrap Road, Vienna, VA 22180 (US). (74) Agents: SANDERCOCK, Colin, G. et al.; Foley & Lard- ner, 1800 Diagonal Road, Alexandria, VA 22313 (US).		(81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CI (OAPI patent), CM (OAPI patent), CS, DE, DE (European patent), DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (Eu- ropean patent), GN (OAPI patent), GR (European pa- tent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MN, MR (OAPI patent), MW, NL, NL (European pa- tent), NO, PL, RO, SD, SE, SE (European patent), SN (OAPI patent), SU*, TD (OAPI patent), TG (OAPI pa- tent). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS FOR LIPOPROTEIN(a) (57) Abstract Peptides which present an epitope substantially similar to the activation site region epitope of apolipoprotein(a) are pro- vided. Antibodies raised against such peptides bind to apolipoprotein(a). Such antibodies and peptides, as well as peptide con- structs for immunization are provided. Also provided are monoclonal antibodies and hybridomas, polyclonal serum, assays, diag- nostic systems in kit form, chromatographic methods and materials, and synthetic secondary standards. Therapeutic composi- tions and methods are also provided.		

+ DESIGNATIONS OF "SU"

Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CJ	Côte d'Ivoire	LI	Liechtenstein	SU+	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS
AND METHODS FOR LIPOPROTEIN(a)

5

FIELD OF THE INVENTION

This invention relates to diagnostic products and methods for determining the presence of lipoprotein(a) or apolipoprotein(a) in a fluid sample such as a blood sample. This invention also relates to therapeutic
10 compositions and methods for decreasing the presence of lipoprotein(a) in a mammal or generating an immune response to lipoprotein(a).

BACKGROUND OF THE INVENTION

Lipoproteins are the primary carriers of plasma
15 cholesterol. They are micellar lipid-protein complexes (particles) having a surface film, comprised of one or more proteins associated with polar lipids, that surround a cholesterol-containing core. Lipoproteins were originally classified based on their buoyant densities as
20 measured by ultracentrifugation. Accordingly, four major density classes have been recognized: chylomicrons, very low-density lipoproteins (VLDL), low-density lipoproteins (LDL) and high-density lipoproteins (HDL).

Studies have established a direct correlation between plasma LDL cholesterol levels and the risk of coronary artery disease (CAD). That is, elevated levels of plasma cholesterol found in LDL particles correlate with an increased risk of CAD. Similarly, many studies have now shown that elevated plasma levels of lipoprotein(a), a component of LDL, evidence a high risk factor for heart disease and atherosclerosis.

The structure of the lipoprotein(a) molecule has been determined to comprise a protein portion identified as apolipoprotein B-100 linked through disulfide bonds to two apolipoprotein(a) molecules. The structure of lipoprotein(a) is similar to that of plasminogen, a blood component involved in vessel wound repair which is activated by proteolytic cleavage at a specific activation site by tissue-type plasminogen activator (t-PA) or urokinase. The region encompassing the plasminogen activation site ("activation site region") differs in amino acid sequence the analogous apolipoprotein(a) region. The sequence around the plasminogen activation site (arginine-valine) is LYS-CYS-PRO-GLY-ARG-VAL-VAL-GLY-GLY, whereas the analogous apolipoprotein(a) sequence is LYS-CYS-PRO-GLY-SER-ILE-VAL-GLY-GLY. See Eaton et al., *Proc. Natl. Acad. Sci. USA*, 84: 3224-3228, 3227 (1987), the disclosure of which is incorporated herein. Moreover, while plasminogen is activated by cleavage by urokinase or t-PA at arginine 560, apolipoprotein(a) may be inactive or not activatable

by streptokinase, urokinase or t-PA. *Id.* For purposes of this disclosure, the above-described region of apolipoprotein(a) that is analogous to the activation site region of plasminogen will be hereinafter referred to as "the activation site region of apolipoprotein(a)." 5

Despite these differences in the plasminogen and analogous apolipoprotein(a) activation site regions, the amino acid sequence of lipoprotein(a) and plasminogen are considerably homologous, each having long, recurring sequences of amino acids called "kringles." Previous attempts to prepare lipoprotein(a) assays have utilized antibodies raised against the entire lipoprotein(a) molecule. The apolipoprotein(a) can be purified by known centrifugation methods, and the purified protein is then injected into animals to raise antibodies. Because of the considerable structural homology between lipoprotein(a) and plasminogen, most of the antibodies raised against the entire lipoprotein(a) molecule have recognized epitopes common to both lipoprotein(a) and plasminogen, i.e., the antibodies cross react with plasminogen. Consequently, such assays have met with limited success because of the low number of antibodies which do not cross react with plasminogen, and because of the uncertainty regarding what those few antibodies which do not cross react are binding to. Further, the ability to perform assays for apolipoprotein(a) have been hampered by the lack of standards against which assay results can be accurately compared. 10 15 20 25

Thus, it has not been easy to directly assay a serum sample for lipoprotein(a) because the plasminogen present in the serum yields a false positive result. For this reason, there is a continuing need for means to determine
5 the presence or absence of lipoprotein(a) in a serum sample without the problem of false positive results due to plasminogen, and a continuing need for a standard against which assay results can be accurately measured.

SUMMARY OF THE INVENTION

10 Accordingly, it is an object of this invention to provide an assay for detecting and/or quantifying the presence of lipoprotein(a) or apolipoprotein(a) in a serum sample, which assay minimizes the interference caused by the presence of plasminogen in the sample.

15 It is also an object to provide peptides that are useful in such assays and for preparing antibodies for carrying out such assays. It is also an object to provide standards against which assay results can be accurately compared.

20 It is a further object to provide compositions and methods for chromatographically separating lipoprotein(a) or apolipoprotein(a) from a sample.

It is also a further object to provide therapeutic compositions and methods for treating mammals in which
25 lipoprotein(a) is present.

In achieving these objects, there has been provided, in accordance with one aspect of this invention, a

peptide which presents an epitope substantially similar to an epitope presented by the activation site region of apolipoprotein(a), wherein antibodies which bind to said peptide also bind to said epitope of said activation site
5 region. In a preferred embodiment, the peptide comprises amino acid residues of the sequence SER-ILE, or its immunological equivalent.

In accordance with another aspect of this invention, a peptide is provided that comprises amino acid residues
10 of the following sequence:

GLU-PRO-LYS-LYS-CYS-PRO-GLY-SER-ILE-VAL-GLY-GLY-CYS-VAL-
ALA

or its immunological equivalent.

Other aspects of this invention provide peptide
15 constructs comprising a carrier onto which is bound a peptide as described above.

Another embodiment of this invention provides a process for preparing an antibody which binds to an epitope presented by the activation site region of apolipoprotein(a). The process comprises immunizing an
20 animal or mammal with a peptide construct as described above, and harvesting the antibodies produced. An antibody so produced by this process is also contemplated.

25 In this regard, antibodies which recognize the above-described peptides, including monoclonal antibodies, are also contemplated. Hybridomas that produce such monoclonal antibodies are also contemplated. Preferred

embodiments include antibodies which exhibit substantially no cross reactivity with plasminogen.

Other embodiments of this invention include assays for determining the presence of lipoprotein(a) or apolipoprotein(a) in a sample. The assays comprise the steps of: contacting the sample with a first antibody which binds to an epitope of the activation site region of apolipoprotein(a); maintaining the first antibody in contact with the sample for a time sufficient to form an apolipoprotein(a)-first antibody reaction product; and then determining whether any apolipoprotein(a)-first antibody reaction product is present.

Other contemplated embodiments of this invention comprise assays for lipoprotein in a sample, wherein the improvement comprises the use of an antibody which binds to an epitope of the activation site region of apolipoprotein(a).

Other contemplated embodiments of this invention comprise diagnostic systems, in kit form, including reagents capable of performing the aforementioned assays.

Other contemplated embodiments comprise synthetic secondary standard peptides against which assay results can be accurately measured. The standards comprise first and second regions separated by a linkage region. The first region comprises amino acid residues in a sequence which will bind a first antibody, and the second region comprises amino acid residues which will bind a second antibody. The linkage region is comprised of a material

(e.g., amino acid residues) to which the first and second antibodies will not bind, and is of sufficient length to minimize steric hindrance in the binding of the first and second antibodies to the first and second regions.

5 Yet other embodiments of this invention comprise a method of chromatographically separating lipoprotein(a) or apolipoprotein(a) from a sample utilizing the above-described antibodies, and chromatographic material comprising such antibodies.

10 Still other embodiments contemplated by this invention include therapeutic compositions comprising antibodies of this invention, and antibody conjugates comprising the antibodies of this invention. Such conjugates can comprise, for example, an agent which
15 cleaves or otherwise alters lipoprotein(a), or which provokes an immune response to the lipoprotein(a)-conjugate complex *per se*. The peptides of this invention can be used to provoke an immune response to lipoprotein(a). Methods of reducing the presence of
20 lipoprotein(a) in a mammal using such therapeutic compositions are also provided.

 Additional objects and advantages of the invention will be set forth in part in the description that follows, and in part will be obvious from the
25 description, or may be learned by practice of the invention. The objects and the advantages of this invention may be realized and obtained by means of the compositions of matter and processes particularly pointed

out in the appended claims.

BRIEF DESCRIPTION OF THE FIGURE

Figure 1 illustrates the proposed structure of a lysine backbone of a peptide construct core in accordance
5 with this invention.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

Surprisingly, it has been discovered that the activation site region of apolipoprotein(a) presents an epitope such that antibodies raised against a peptide
10 that is substantially similar to this epitope will recognize and bind native apolipoprotein(a). In particular, a peptide that comprises a serine-isoleucine (SER-ILE) sequence or its immunological equivalent, together with sufficient adjacent amino acid residues
15 from the apolipoprotein(a) activation site region or their immunological equivalents to form an epitope substantially similar to that presented by the activation site region of apolipoprotein(a), can be used to raise antibodies which will recognize and bind
20 apolipoprotein(a). Further, it has been discovered that antibodies raised against a peptide within this invention may exhibit little or no cross reactivity with plasminogen and, hence, are useful in assaying for or separating lipoprotein(a) in or from serum.

25 Based on this discovery, assays for lipoprotein(a) can now be performed without the problem of plasminogen

interference. At least two basic types of assays can thus be performed in accordance with this invention. In the first, a protease (e.g., urokinase, streptokinase or tPA), which recognizes the activation site of plasminogen but not that of apolipoprotein(a), can be added to the serum sample to be assayed. The plasminogen is cleaved and thus presents no epitope similar to that of the activation site region of apolipoprotein(a). Therefore, even if the antibodies which have been raised against the peptides of this invention do exhibit cross reactivity with plasminogen, the only intact activation site region present in the sample after addition of enzyme will be that of apolipoprotein(a). Thus, the antibodies substantially will bind only to apolipoprotein(a). In the other basic type of assay, antibodies which substantially do not cross react with plasminogen are used. In such assays, there is no need first to treat the sample with a protease to cleave the plasminogen. Instead, using conventional assay formats, the sample can be immediately assayed for apolipoprotein(a) without the problem of plasminogen interference. The selection of such antibodies is discussed below.

Both of the foregoing types of assays are contemplated and within the scope of this invention. Those of ordinary skill may readily appreciate other types of assays which can also be carried out using the biological products taught herein. Many different types of assay formats -- sandwich, competitive,

precipitation, homogeneous, heterogenous, etc. -- can be used for the foregoing types of assays.

A. Definitions

The following definitions are provided for some of the terms used throughout this specification.

Amino Acid Residues - identified herein are in the natural L-configuration. The following abbreviations for amino acid residues are used:

	<u>SYMBOL</u>		<u>AMINO ACID</u>
	<u>1-Letter</u>	<u>3-Letter</u>	
10	Y	Tyr	L-tyrosine
	G	Gly	glycine
	F	Phe	L-phenylalanine
	M	Met	L-methionine
15	A	Ala	L-alanine
	S	Ser	L-serine
	I	Ile	L-isoleucine
	L	Leu	L-leucine
	T	Thr	L-threonine
20	V	Val	L-valine
	P	Pro	L-proline
	K	Lys	L-lysine
	H	His	L-histidine
	Q	Gln	L-glutamine,
25	E	Glu	L-glutamic acid
	W	Trp	L-tryptophan
	R	Arg	L-arginine

D	Asp	L-aspartic acid
N	Asn	L-asparagine
C	Cys	L-cysteine

5 All amino acid residue sequences are represented herein by formulae whose left to right orientation is in the conventional direction of amino-terminus to carboxy-terminus.

10 **Peptide** - is used herein to designate a linear series of amino acid residues connected one to the other by peptide bonds between the alpha-amino and carboxy groups of adjacent residues. Peptide, as used herein, does not refer to a naturally occurring protein such as lipoprotein(a) or apolipoprotein(a).

15 **Protein** - refers to any naturally occurring combination of amino acid residues.

20 **Antibody** - in its various grammatical forms is used herein as a collective noun that refers to a population of immunoglobulin molecules and/or immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an "antigen binding site" or paratope. An antigen binding site is that structural portion of an antibody molecule that specifically binds an antigen.

25 **Exemplary antibodies** are intact immunoglobulin molecules, substantially intact immunoglobulin molecules and those portions of an immunoglobulin molecule that contain the paratope, including those portions known in the art as Fab, Fab', F(ab')₂ and F(v).

Fab and F(ab')₂ portions of antibodies can be

prepared by the proteolytic reaction of papain and pepsin, respectively, on substantially intact antibodies by methods that are well known. See for example, U.S. Patent No. 4,342,566 to Theofilopolous and Dixon. Fab' antibody portions are also well known and are produced from $F(ab')_2$ portions followed by reduction of the disulfide bonds linking the two heavy chain portions as with mercaptoethanol, and followed by alkylation of the resulting protein mercaptan with a reagent such as iodoacetamide. Antibodies and binding fragments can also be produced by recombinant methods, which are well known to those skilled in the art. See, for example, U.S. Patent 4,946,778 to Ladner et al.

The antibodies may also be catalytic antibodies, which are capable of binding to the protease site of apolipoprotein(a) and catalyzing a reaction. Catalytic antibodies are well known to those skilled in that art; see, for example, "Catalytic Antibodies," *C&EN*, pp. 26-40 (May 28, 1990), the disclosure of which is incorporated herein.

Polyclonal serum - refers to serum comprising antibodies generated by one or more animals in response to being injected with the peptide constructs of this invention.

Monoclonal antibody - in its various grammatical forms refers to a population of antibody molecules that contains only one species of antibody combining site capable of immunoreacting with a particular antigen. A

monoclonal antibody thus typically displays a single binding affinity for any antigen with which it immunoreacts. A monoclonal antibody may therefore comprise an antibody molecule having a plurality of antibody combining sites, each immunospecific for a different antigen, e.g., a bispecific or "bifunctional" monoclonal antibody.

Methods for determining the affinity of a monoclonal antibody for an antigen and comparing those affinities for equivalence are well known in the art. See, for example, Muller, *J. Immunol. Meth.*, 34:345352 (1980) and Sokal et al., *Biometry.*, W. H. Freeman & Co., (1981).

B. The Peptides

In order to construct a diagnostic immunoassay capable of identifying the presence and, optionally, the quantity of lipoprotein(a) in blood plasma, an immunological means such as an antibody is required for separating the lipoprotein(a) from other blood components. For the antibody to be effective in binding lipoprotein(a), it must be directed to an epitope appearing on the surface of the molecule. With lipoproteins, where the surface proteins surround and are imbedded in globules of lipid in a dynamic state, it is desirable to select antibodies against epitopes which are on the surface of the lipids substantially at all times.

Further, in a molecule such as lipoprotein(a) where the primary structure is associated in a variable number

of repetitious segments called "kringles" which vary in number and surface availability, the selection of an epitope which appears only once in each molecule acquires added importance. Further still, in a serum assay for lipoprotein(a) or apolipoprotein(a), it may be desirable that the antibodies used substantially will not cross react with plasminogen present in the serum sample.

It has been discovered that antibodies raised against a peptide which presents an epitope substantially similar to the epitope presented by the activation site region of apolipoprotein(a) can apparently satisfy all of the foregoing criteria.

In accordance with the foregoing, a peptide which presents an epitope substantially similar to an epitope of the activation site region in apolipoprotein(a) can be synthesized. A peptide in accordance with this invention can first comprise a serine-isoleucine (SER-ILE) sequence or its immunological equivalent. The peptide can also comprise one or several amino acid residues adjacent to either or both the serine and isoleucine. The adjacent residues should comprise amino acid residues from the activation site region of apolipoprotein(a) or their immunological equivalents. By immunological equivalent, it is meant that certain amino acid residue substitutions and/or deletions can possibly be made in peptides which repeat part or all of the activation site region sequence of apolipoprotein(a), and yet the new peptide will provoke a substantially similar immune response. Such

substitutions and/or deletions can be made in accordance with established principles, some of which are briefly discussed below, to yield a peptide which can be used to raise antibodies which behave substantially the same as antibodies raised against a peptide having the natural sequence. In this regard, antibodies which bind to an epitope of the activation site region of apolipoprotein(a) are considered to be equivalents. Thus, to be an immunological equivalent, it is not necessary that each residue of the natural apolipoprotein(a) activation site region sequence or fragment thereof be replaced with an immunologically equivalent residue, but rather that the peptide as a whole evokes a substantially similar immune response.

15 Thus, in a peptide in accordance with this invention, the serine (of the serine-isoleucine dimer) or an immunological equivalent of the serine can, for example, have attached to it the following residues or their immunological equivalents:

20 GLY-
PRO-GLY-
CYS-PRO-GLY-
LYS-CYS-PRO-GLY-
LYS-LYS-CYS-PRO-GLY-
25 PRO-LYS-LYS-CYS-PRO-GLY-
GLU-PRO-LYS-LYS-CYS-PRO-GLY-

and so forth. Similarly, the isoleucine of the serine-isoleucine dimer, or the immunological equivalent of

isoleucine can, for example, have attached to it the following residues or their immunological equivalents:

-VAL

-VAL-GLY

5

-VAL-GLY-GLY

-VAL-GLY-GLY-CYS

-VAL-GLY-GLY-CYS-VAL

-VAL-GLY-GLY-CYS-VAL-ALA

and so forth. Alternatively, the above residues can be
10 attached onto one or more amino acid residues which
present an immunological equivalent to the SER-ILE dimer
itself, or the corresponding residues can be attached
onto one or more amino acid residues which present an
immunological equivalent to the GLY-SER-ILE or SER-ILE-
15 VAL trimers, and so forth (e.g., tetramers, pentamers,
etc.). Likewise, preparation of many other permutations
and combinations within the scope of this invention is
well within the ordinary skill in this art, and
determining which peptides evoke the desired immune
20 response will involve only routine experimentation.

Thus, substitutions of one amino acid for another,
either conservative or non-conservative, where such
changes provide for certain advantages in their use are
contemplated. Conservative substitutions are those where
25 one amino acid residue is replaced by another,
biologically similar residue. Examples of conservative
substitutions include the substitution of one hydrophobic
residue such as isoleucine, valine, leucine or methionine

for another, or the substitution of one polar residue for another such as between arginine and lysine, between glutamic and aspartic acids or between glutamine and asparagine and the like. Conservative substitutions also
5 include the use of a substituted amino acid in place of an unsubstituted parent amino acid provided that such a peptide also displays the requisite binding activity.

A peptide in accordance with this invention which has a sequence that is not identical to the sequence of the
10 activation site region of apolipoprotein(a) (because one or more conservative or nonconservative substitutions and/or deletions have been made) will usually have no more than about 30 number percent, advantageously no more than about 20 number percent, and preferably no more than
15 about 10 number percent of the amino acid residues which comprise all or part of the activation site region of apolipoprotein(a) substituted or deleted, except where additional residues have been added at either terminus for the purpose of providing a "linker" by which the
20 peptides of this invention can be conveniently affixed to a label, a solid matrix, or a carrier. Labels, solid matrices and carriers that can be used with the peptides of this invention are described below.

Amino acid residue linkers usually comprise at least
25 one amino acid residue and can comprise 40 or more residues, more often 1 to 10 residues. The linker residues do not form lipoprotein(a) epitopes, i.e., they are not similar in structure to the lipoprotein(a).

Typical amino acid residues used for linking are glycine, alanine, serine, threonine, or the like. In addition, the amino acid residue sequence of a peptide in accordance with this invention can differ, unless
5 otherwise specified, from the natural sequence of the activation site region of apolipoprotein(a) by the sequence being modified by terminal-NH₂ acylation, e.g., acetylation.

The length of the peptides of this invention can
10 vary, for example, depending on the type of carrier used for immunization. It is generally preferred that the peptide be of a length which minimizes the number of epitopes other than the desired epitope so that the population of antibodies raised against the peptide will
15 contain a greater concentration of the desired antibodies. Moreover, when preparing the peptides by chemical synthesis, additional residues will generally lengthen the time required for their preparation. Peptides which also present epitopes in addition to that
20 of the apolipoprotein(a) activation site region are, however, certainly also within the scope of this invention. Routine experimentation will yield the optimum length(s).

As but one example, it has been found that a peptide
25 having the following sequence of amino acid residues:

GLU-PRO-LYS-LYS-CYS-PRO-GLY-SER-ILE-VAL-GLY-GLY-CYS-
VAL-ALA

is very useful in preparing antibodies which bind to the

activation site region of apolipoprotein(a). The length was chosen because of the type of peptide construct which was to be used.

A peptide in accordance with this invention can be synthesized by any of the techniques that are known to those skilled in the peptide art, including recombinant DNA techniques. Synthetic chemistry techniques, such as a solid-phase Merrifield-type synthesis, are preferred for reasons of purity, antigenic specificity, freedom from undesired side products, ease of production and the like. An excellent summary of the many techniques available can be found in J.M. Steward and J.D. Young, "Solid Phase Peptide Synthesis," W.H. Freeman Co., San Francisco, (1969); M. Bodanszky et al., "Peptide Synthesis," John Wiley & Sons, Second Edition, (1976); and J. Meienhofer, "Hormonal Proteins and Peptides," Vol. 2, p. 46, Academic Press, New York (1983) for solid phase peptide synthesis, and E. Schroder and K. Kubke, 1 THE PEPTIDES, Academic Press, New York (1965) for classical solution synthesis, each of which is incorporated herein by reference. Appropriate protective groups usable in such synthesis are described in the above texts and in J.F.W. McOmie, PROTECTIVE GROUPS IN ORGANIC CHEMISTRY, Plenum Press, New York (1973), which is also incorporated herein by reference.

In general, the solid-phase synthesis methods contemplated comprise the sequential addition of one or more amino acid residues or suitably protected amino acid

residues to a growing peptide chain. Normally, either the amino or carboxyl group of the first amino acid residue is protected by a suitable, selectively-removable protecting group. A different, selectively-removable protecting group is utilized for amino acids containing a reactive side group such as lysine.

Using a solid phase synthesis as exemplary, the protected or derivatized amino acid is attached to an inert solid support through its unprotected carboxyl or amino group. The protecting group of the amino or carboxyl group is then selectively removed and the next amino acid in the sequence having the complimentary (amino or carboxyl) group suitably protected is admixed and reacted under conditions suitable for forming the amide linkage with the residue already attached to the solid support. The protecting group of the amino or carboxyl group is then removed from this newly added amino acid residue, and the next amino acid (suitably protected) is then added, and so forth. After all the desired amino acids have been linked in the proper sequence, any remaining terminal and side group protecting groups (and solid support) are removed sequentially or concurrently, to afford the final peptide.

C. The Peptide Constructs

When coupled to a carrier to form a peptide construct, the peptides of this invention are capable of

inducing antibodies that bind to the activation site region of apolipoprotein(a). The preparation of peptide constructs is well known to those skilled in that art. While many different types of constructs are contemplated, preferred constructs have been assembled according to the Multiple Antigen Peptide System of Tam et al, "Synthetic Peptide Vaccine Design," *Proc. Natl. Acad. Sci. USA*, **85**: 5409-5413 (August 1988). It has been found that constructs prepared in accordance with the procedure of Tam et al. yield sera comprising antibodies which are highly specific for lipoprotein(a).

Following the procedure of Tam et al. a construct in accordance with this invention having a molecular weight of about 12,000 daltons was prepared. (See Examples 1-3.) The construct comprised a core of 7 lysine residues containing 8 copies of the peptide each separated from the core by a tri-glycine extender and has the following structure:

β Ala-Lys-(Lys₂)-(Lys₄)-((Gly₃)-Ala-Val-Cys-Gly-Gly-Val-Ile-Ser-Gly-Pro-Cys-Lys-Lys-Pro-Glu-OAc)₈.

The construct was generally prepared as follows. First, a core consisting of 7 lysine residues was constructed on a base of β Ala-OCH₂-Pam resin according to the manual synthesis method of Merrifield (*J. Amer. Chem. Soc.* **85**, 2149-2154 (1963)). A triglycyl linker was then added followed by the sequential addition of the amino acids in the peptide chain. The chains were acetylated on their -NH₂ terminal ends prior to removal from the Pam

resin to decrease the total charge present on the construct. The constructs were monitored closely during the sequential addition of amino acids to assure better than 99% coverage of free amino groups to minimize
5 deletion peptides, which are difficult or impossible to detect in the finished construct. The constructs were then dialyzed extensively following removal from the resin in denaturing and reducing conditions to remove any byproducts of the cleavage reaction. The constructs were
10 then lyophilized and utilized for inoculations in complete Freund's adjuvant without further purification.

An amino acid analysis of the peptide construct was performed. The presence of free sulfhydryl groups was demonstrated by dinitrobenzene analysis (*J. Biochem.*,
15 89:296 (1963)). An agarose electrophoresis was performed, which, upon staining for protein utilizing Sudan black, demonstrated a single diffuse band.

In addition to being useful for raising antibodies, the peptide constructs of this invention are useful for
20 assays such as ELISA testing for lipoprotein(a) and apolipoprotein(a) antibodies and for affinity purification of lipoprotein(a) and apolipoprotein(a) antibodies, and for use in provoking immune responses against lipoprotein(a) in mammals. Other uses will be
25 readily apparent to those skilled in the art.

D. The Antibodies

As stated above, antibodies in accordance with this

invention are those which bind to an epitope on the activation site region of apolipoprotein(a). Substantially purified quantities of monoclonal or polyclonal antibodies can thus be prepared. Such antibodies may exhibit some affinity toward plasminogen. Their affinity to plasminogen, however, preferably will be small in comparison to their affinity to lipoprotein(a) and apolipoprotein(a). For example, preferred antibodies in accordance with this invention are those which exhibit an affinity to apolipoprotein(a) that is greater than their affinity to plasminogen by a factor of 2, 5, 10, 100, 1000, 10000 or more. Methods for preparing antibodies from constructs such as those described above are well known and are not repeated in detail here. Polyclonal sera can be obtained, for example, from mice that have been immunized with such constructs. (See Example 4.) Monoclonal antibodies can then be prepared using routine methods, for example, from cells obtained from the immunized mice. (See Example 5.) Exemplary procedures for obtaining monoclonal antibodies and hybridomas in accordance with this invention are as follows. Other procedures may be known to those skilled in that art.

A monoclonal antibody in accordance with this invention, typically containing whole antibody molecules, can be prepared using the peptide-induced hybridoma technology described by Niman et al., *Proc. Natl. Sci., USA*, 80:4949-4953 (1983), which description is

incorporated herein by reference. Briefly, to form the hybridoma from which the monoclonal antibody composition is produced, a myeloma or other self-perpetuating cell line is fused with lymphocytes obtained from the spleen
5 of a mammal hyperimmunized with a peptide of this invention.

It is preferred that the myeloma cell line be from the same species as the lymphocytes. Typically, a mouse, for example of the strain 129 GLX+, is the preferred
10 mammal. Suitable mouse myelomas for use in the present invention include the hypoxanthine-aminopterin-thymidine-sensitive (HAT) cell lines P3X63-Ag8.653, and Sp2/O-Ag14 that are available from the American Type Culture Collection, Rockville, MD, under the designations CRL
15 1580 and CRL 1581, respectively.

Splenocytes are typically fused with myeloma cells using polyethylene glycol (PEG) 1500. Fused hybrids are selected by their sensitivity to HAT. Hybridomas producing a monoclonal antibody of this invention can be
20 identified by an assay such as a radioimmunoassay (RIA) or a sandwich assay.

A monoclonal antibody of the present invention can be produced by initiating a monoclonal hybridoma culture comprising a nutrient medium containing a hybridoma that
25 secretes antibody molecules of the appropriate peptide specificity. The culture is maintained under conditions and for a time period sufficient for the hybridoma to secrete the antibody molecules into the medium. The

antibody-containing medium is then collected. The antibody molecules can then be further isolated by well known techniques.

Media useful for the preparation of these
5 compositions are both well known in the art and commercially available and include synthetic culture media, inbred mice and the like. An exemplary synthetic medium is Dulbecco's minimal essential medium (DMEM; Dulbecco et al., *Virology* 8:396 (1959)) supplemented with
10 4.5 gm/l glucose, 20 mm glutamine, and 20% fetal calf serum. An exemplary inbred mouse strain is the Balb/c.

The monoclonal antibody produced by the above method can be used, for example, in diagnostic and therapeutic modalities wherein formation of an lipoprotein(a)- or
15 apolipoprotein(a)-containing immunoreaction product is desired.

Antibodies in accordance with this invention can be screened according to their affinities to (1) the peptides against which they were raised, (2)
20 lipoprotein(a) or apolipoprotein(a), and/or (3) plasminogen. Preferred antibodies will exhibit high affinities for lipoprotein(a) or apolipoprotein(a), low affinities for plasminogen, and at least some affinity for the peptide against which they were raised.

25 E. Assays and Diagnostic Systems

The present invention contemplates various immunoassay methods for determining the amount of

lipoprotein(a) or apolipoprotein(a) in a biological fluid sample using a peptide and/or antibodies of this invention. The peptide or antibody comprises immunochemical reagents for forming an immunoreaction product whose presence or amount relates, either directly or indirectly, to the presence or amount of lipoprotein(a) or apolipoprotein(a) in the sample. Those skilled in the art will appreciate that there are numerous well known clinical diagnostic chemistry procedures in which the immunochemical reagents of this invention can be used to form an immunoreaction product whose presence and/or amount relates to the presence and/or amount of lipoprotein(a) or apolipoprotein(a) present in a body sample.

Thus, while exemplary assay methods are described herein, the invention is not so limited. Various heterogenous and homogeneous protocols, either competitive or noncompetitive, can be employed in performing an assay method of this invention. As stated above, the assays of this invention can also utilize a protease such as urokinase, streptokinase or t-PA for treating the sample to cleave any plasminogen present. Such a step may always be used and those of ordinary skill will readily appreciate the manner in which such proteases may be employed. It may, however, be preferable in terms of time, simplicity and expense to use such proteases only when the antibodies used exhibit more than minimal affinity toward plasminogen.

For example, the present invention contemplates a double antibody or "sandwich" immunoassay comprising the steps of: (a) forming a first immunoreaction admixture by admixing a vascular fluid sample with a first antibody, e.g., a monoclonal antibody, wherein the antibody and apolipoprotein(a) present in the sample are capable of forming a first immunoreaction product (the first antibody can be operatively linked to a solid matrix); (b) maintaining the first immunoreaction admixture so formed under biological assay conditions for a time period sufficient to form the first immunoreaction product (the first immunoreaction product can then be separated from the sample); (c) forming a second immunoreaction admixture by admixing the first immunoreaction product with a second antibody, monoclonal or polyclonal, which recognizes lipoprotein(a) or apolipoprotein(a); (d) maintaining the second immunoreaction admixture so formed under biological assay conditions for a period sufficient to form the second or "sandwich" immunoreaction product; and (e) determining the presence and, optionally, the amount of second immunoreaction product formed, and thereby the presence and, optionally, the amount of lipoprotein(a) or apolipoprotein(a) in the sample.

Preferably, the second antibody is labeled, preferably with an enzyme, and thus the second immunoreaction product formed will be a labeled product.

In preferred double antibody assay methods, the

amount of immunoreaction product determined is related to the amount of immunoreaction product similarly formed and determined using a standard sample in place of the vascular fluid sample, wherein the standard sample
5 contains a known amount of lipoprotein(a) or apolipoprotein(a) in accordance with this invention. Alternatively, a synthetic secondary standard (see, e.g., Example 11) can be used.

It is also preferred that the second antibody be
10 directed to a site on the lipoprotein(a) or apolipoprotein(a) which is not the same as the site to which the first antibody is directed, i.e., not the activation site region of apolipoprotein(a). For example, the second antibody can be an anti-B-100
15 antibody, an anti-plasminogen antibody, or another anti-apolipoprotein(a) antibody directed to a site other than the activation site region of apolipoprotein(a), e.g., the N-terminal or C-terminal.

The vascular fluid sample can be provided as a known
20 or unknown quantity of blood, or a blood derived product such as serum or plasma. The amount of antibody used can be known or unknown. The admixture is maintained under biological assay conditions for a predetermined period of from about a few seconds to about 20 hours at a
25 temperature of from about 4 degrees C to about 45 degrees C, advantageously room temperature, i.e., about 25 degrees C.

Biological assay conditions are those that maintain

the biological activity of the immunochemical reagents of this invention and the lipoprotein(a) and apolipoprotein(a). Those conditions can generally include a temperature range of from about 4 to about 5 45°C, a pH value range of from about 5 to about 9, and an ionic strength varying from about that of distilled water to about one molar sodium chloride. Upon routine experimentation, other biological assay conditions may be learned. Methods for optimizing such conditions are well 10 known to those skilled in the art.

Another assay format that is preferred is the precipitation assay. In this embodiment, the process comprises formation of an immunoreaction admixture by admixing a vascular fluid sample with a first antibody 15 (which can be from polyclonal sera) to yield an precipitous immunoreaction product. The antibody can be operatively linked to a solid particulate such as a microparticle or bead, such that when antibody-antigen crosslinking occurs, the particulate matter aggregates, 20 indicating the presence of the target material.

Many other types of assays within the scope of this invention will be readily apparent to those skilled in the art.

A diagnostic system, in kit form, of the present 25 invention generally comprises, in an amount sufficient for at least one assay, an antibody within the scope of this invention and a means for detecting an immunoreaction product comprising the antibody and

apolipoprotein(a) as packaged immunochemical reagents. Instructions for use of a packaged immunochemical reagent are also typically included.

As used herein, the term "packaged" can refer to the use of a solid matrix or material such as glass, plastic, paper, fiber, foil and the like capable of holding within fixed limits an antibody of this invention. Thus, for example, a package can be a glass vial used to contain milligram quantities of a contemplated antibody or it can be a microtiter plate well to which microgram quantities of a contemplated antibody has been operatively affixed. Alternatively, a package could include antibody-coated microparticles entrapped within a porous membrane or imbedded in a test strip or dipstick, etc. Alternatively, the antibody can be directly coated onto a membrane, test strip or dipstick, etc. which contacts the sample fluid. Many other possibilities exist and will be readily recognized by those skilled in this art.

Instructions for use typically include a tangible expression describing the reagent concentration or at least one assay method parameter such as the relative amounts of reagent and sample to be admixed, maintenance time periods for reagent/sample admixtures, temperature, buffer conditions and the like.

In preferred embodiments, a diagnostic system of the present invention further includes a label or indicating means capable of signaling the formation of a complex containing an antibody of the present invention.

The word "complex" as used herein refers to the product of a specific binding reaction such as an antibody-antigen or receptor-ligand reaction. Exemplary complexes are immunoreaction products.

5 As used herein, the terms "label" and "indicating means" in their various grammatical forms refer to single atoms and molecules that are either directly or indirectly involved in the production of a detectable signal to indicate the presence of a complex. Any label
10 or indicating means can be linked to or incorporated in an expressed protein, peptide, or antibody molecule that is part of the present invention, or used separately, and those atoms or molecules can be used alone or in conjunction with additional reagents. Such labels are
15 themselves well known in clinical diagnostic chemistry.

 The labeling means can be a fluorescent labeling agent that chemically binds to antibodies or antigens without denaturing them to form a fluorochrome (dye) that is a useful immunofluorescent tracer. Suitable
20 fluorescent labeling agents are fluorochromes such as fluorescein isocyanate (FIC), fluorescein isothiocyanate (FITC), 5-dimethylamine-1-naphthalenesulfonyl chloride (DANSC), tetramethylrhodamine isothiocyanate (TRITC), lissamine, rhodamine 8200 sulphonyl chloride (RB 200 SC)
25 and the like. A description of immunofluorescence analysis techniques is found in DeLuca, "Immunofluorescence Analysis", in *Antibody As a Tool*. Marchalonis, et al., eds., John Wiley & Sons, Ltd., pp.

189-231 (1982), which is incorporated herein by reference.

In preferred embodiments, the indicating group is an enzyme, such as horseradish peroxidase (HRP), glucose oxidase, or the like. In such cases where the principle indicating group is an enzyme such as HRP or glucose oxidase, additional reagents are required to indicate that a receptor-ligand complex (immunoreactant) has formed. Such additional reagents for HRP include hydrogen peroxide and an oxidation dye precursor such as diaminobenzidine. An additional reagent useful with glucose oxidase is 2,2'-azino-di-(3-ethyl-benzthiazoline-6-sulfonic acid) (ABTS).

Radioactive elements are also useful labeling agents and are used illustratively herein. An exemplary radiolabeling agent is a radioactive element that produces gamma ray emissions. Elements which themselves emit gamma rays, such as ^{124}I , ^{125}I , ^{128}I , ^{132}I and ^{51}Cr represent one class of gamma ray emission-producing radioactive element indicating groups. Particularly preferred is ^{125}I . Another group of useful labeling means are those elements such as ^{11}C , ^{18}F , ^{15}O and ^{13}N which themselves emit positrons. Also useful is a beta emitter, such as ^{111}In or ^3H . Catalytic antibodies which do or do not bind to the activation site region of apolipoprotein(a) can also be employed for labeling purposes.

The linking of labels, i.e., labeling of peptides and

proteins is well known in the art. For instance, monoclonal antibodies produced by a hybridoma can be labeled by metabolic incorporation of radioisotope-containing amino acids provided as a component in the culture medium. See, for example, Galfre et al., *Meth. Enzymol.*, 73:3-46 (1981). The techniques of protein conjugation or coupling through activated functional groups are particularly applicable. See, for example, Aurameas et al., *Scand. J. Immunol.*, Vol. 8 Suppl. 7:7-23 (1978), Rodwell et al., *Biotech.*, 3:889-894 (1984), and U.S. Patent No. 4,493,795.

The diagnostic systems can also include, preferably as a separate package, a "specific binding agent," which is a molecular entity capable of selectively binding an antibody or peptide of this invention or a complex containing such a species, but is not itself a peptide or antibody of this invention. Exemplary specific binding agents are second antibody molecules, complement proteins or fragments thereof, *S. aureus* protein A, and the like. Preferably the specific binding agent binds the antibody or peptide when it is present as part of a complex.

In preferred embodiments, the specific binding agent is labeled. However, when the diagnostic system includes a specific binding agent that is not labeled, the agent is typically used as an amplifying means or reagent. In these embodiments, the labeled specific binding agent is capable of specifically binding the amplifying means when the amplifying means is bound to a complex.

The diagnostic kits can also include proteases such as urokinase, streptokinase or t-PA.

The diagnostic kits of the present invention can be used in an "ELISA" format to detect the quantity of lipoprotein(a) or apolipoprotein(a) in a vascular fluid sample such as blood, serum, or plasma. "ELISA" refers to an enzyme linked immunosorbent assay such as those discussed above, which employ an antibody or antigen bound to a solid phase and an enzyme-antigen or enzyme-antibody conjugate to detect and quantify the amount of an antigen present in a sample. A description of the ELISA technique is found in Chapter 22 of the 4th Edition of *Basic and Clinical Immunology*, D.P. Sites et al., Lange Medical Publications of Los Altos, CA (1982), and in U.S. Patents No. 3,654,090, 3,850,752, and 4,016,043, which are all incorporated herein by reference.

Thus, in preferred embodiments, a peptide or antibody of this invention can be affixed to a solid matrix to form a solid support. A reagent is typically affixed to a solid matrix by adsorption from an aqueous medium although other modes of affixation applicable to proteins and peptides well known to those skilled in the art, can be used.

Useful solid matrices are also well known in the art. Such materials are water insoluble and include the cross-linked dextran available under the trademark SEPHADEX from Pharmacia Fine Chemicals (Piscataway, NJ); agarose; polystyrene beads about 1 micron to about 5 millimeters

in diameter polyvinyl chloride, polystyrene, cross-linked polyacrylamide, nitrocellulose- or nylon-based webs such as sheets, strips or paddles; or tubes, plates or the wells of a microtiter plate such as those made from polystyrene or polyvinylchloride.

The peptide, antibody, proteases, specific binding agent or amplifying reagent of any diagnostic system described herein can be provided in solution, as a liquid dispersion or as a substantially dry power, e.g., in lyophilized form. Where the indicating means is an enzyme, the enzyme's substrate can also be provided in a separate package. A solid support such as the above-described microtiter plate and one or more buffers can also be included as separately packaged elements in the diagnostic assay systems of this invention.

The packaging materials discussed herein in relation to diagnostic systems are those customarily utilized in diagnostic systems. Such materials include glass and plastic (e.g., polyethylene, polypropylene and polycarbonate) bottles, vials, plastic and plastic-foil laminated envelopes and the like.

F. Therapeutic Compositions

The peptides, constructs and antibodies of this invention can also be used for therapeutic purposes. For example, the antibodies can be used by themselves, or they can be used to prepare therapeutic conjugates in which an antibody is conjugated to an agent which in some

way alters lipoprotein(a), e.g., by cleavage, or which provokes an immune response to the apolipoprotein(a)-conjugate complex such that the entire complex is destroyed or removed by the host's immune system. In this way, the presence of lipoprotein(a) in the bloodstream could be reduced. When preparing such conjugates, it is preferred that the antibodies used exhibit substantially no cross reactivity toward plasminogen, which is an essential component of the blood.

Agents which can be conjugated to antibodies to provoke an immune response include toxins such as diphtheria toxin and vaccinia virus, which are commonly recognized by the body (of immunized persons) and eliminated by the immune system.

The peptides and constructs of this invention can be used to provoke a temporary or prolonged immune response in a host mammal against lipoprotein(a). Those skilled in the art of preparing pharmaceutical compositions will realize how to prepare the antibodies, conjugates, peptides and constructs described above for pharmaceutical use using accepted pharmaceutical carriers.

The following Examples are provided solely for illustrative purposes, and do not in any manner limit this invention.

EXAMPLE 1

SYNTHESIS OF A LIPOPROTEIN(a)
PEPTIDE CONSTRUCT CORE

One gram of t-butoxycarbonyl (Boc) β ala-OCH₂-PAM resin, substituted with β -alanine at a level of 0.01 millimole per gram of resin, was prepared according to the procedure of Merrifield et al. (*J. Org. Chem.* 43: 2845-2852 (1978)). The Boc protective group was removed by treatment of the resin with three changes of 15 ml trifluoroacetic acid in dichloromethane (1:1) for a total of 60 minutes at 22°C. The resin was then neutralized by treatment with 20 ml triethylamine in dichloromethane (1:9) for 20 minutes at 22°C, washed 3 times with 20 ml of dichloromethane and 3 times with 20 ml of dimethylformamide and placed into a solid state synthesis reaction vessel.

A symmetrical anhydride of N_α,N_ε-di t-Boc-L-lysine was prepared by dissolving 1 millimole of N_α,N_ε-di t-Boc-L-lysine in 3 ml dimethylformamide. The solution was cooled to 0°C and 2 ml dimethylformamide containing 2 millimoles of dicyclohexylcarbodiimide at 0°C was added. The reaction was allowed to proceed for one hour at 0°C and the solution was then warmed to 22°C. The anhydride was then filtered through a Buchner funnel onto the resin sample and the reaction vessel was then rocked at 18 cycles per minute for 2 hours at 22°C. A sample of approximately 1 mg of the resin was then removed and assayed for completeness of reaction using the ninhydrin procedure described by Merrifield et al., (*Analytical Biochemistry*, 117: 147-157 (1981)). A second coupling

was performed to force the reaction to a more complete state by equilibrating the resin in dichloromethane, adding 1 millimole of N_α, N_ϵ -di t-Boc-L-lysine in 5 ml dichloromethane, rocking for 10 minutes at 22°C, adding
5 2 millimoles of dicyclohexylcarbodiimide and rocking for 17 hours at 22°C. A subsequent ninhydrin assay indicated better than 99% completeness of reaction.

The Boc protective groups were then removed by treating the resin with 15 ml of a 1:1 solution of
10 trifluoroacetic acid in dichloromethane containing 1 mg per ml of indole for 30 minutes with one change of reaction solvent at 15 minutes. The resin was then neutralized by treatment with 15 ml of 5% diisopropyl-ethylamine in dichloromethane for 30 minutes and
15 subsequently washed with three 15 ml aliquots of dichloromethane and three 15 ml aliquots of dimethylformamide.

The addition of the second lysine residue layer to the carrier backbone was accomplished by adding two
20 millimoles of N_α, N_ϵ -di t-Boc-L-lysine to four millimoles of dicyclohexyl-carbodiimide in a total volume of 15 ml of dimethylformamide at 0°C to form a symmetrical anhydride which was then subsequently reacted with the
25 free amine groups on the resin for 3 hours at 22°C. At the end of the second hour, an additional four millimoles of dicyclohexyl-carbodiimide in dimethylformamide was added. The resin was then washed with dichloromethane (3 x 20 ml) and the completeness of the reaction was

determined by ninhydrin determination of the free amine content. The Boc protective groups were then removed as previously described.

The addition of the third lysine residue layer to the carrier backbone was accomplished by adding four millimoles of N_α, N_ϵ -di t-Boc-L-lysine to eight millimoles of dicyclohexyl-carbodiimide in a total volume of 15 ml of dimethylformamide at 0°C to form a symmetrical anhydride which was then subsequently reacted with the free amine groups on the resin for one hour at 22°C. The resin was then washed with dichloromethane. Resin aggregates were broken up by passing the resin through a fine stainless steel mesh filter, and the coupling was reinitiated using the identical reaction conditions stated above, but substituting dichloromethane for dimethylformamide. Reaction of the lysine residues with the resin free amines was shown to be better than 99% complete by ninhydrin analysis. The resin was treated with trifluoroacetic acid: dichloromethane with 1 mg per ml of indole to remove the Boc protective groups. A quantitative ninhydrin analysis of the deprotected resin indicated an amine content of 0.08 millimole per gram or eight times the free amine content of the starting material, consistent with the proposed structure of the lysine backbone as shown in Figure 1.

A triglycine chain extender was now added to each free amine group by the sequential addition of three glycine residues. A solution was prepared by dissolving

0.7 millimole of Boc-glycine in 3 ml of dimethylformamide. The solution was cooled to 4°C and 0.7 millimole 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide in 7 ml of dimethylformamide was added.

5 The solution was allowed to stand for 1 hour at 4°C, warmed to 22°C and filtered onto the resin which was then rocked for 2 hours at 22°C. The resin was then checked for completeness of coupling using the ninhydrin assay for free amines. If the reaction was not complete the

10 resin was washed with dichloromethane and the coupling procedure reinitiated as described above. When the reaction was found to be better than 99% complete the Boc groups were removed using the trifluoroacetic acid : dichloromethane : indole procedure as previously

15 described and the next glycine residue added as above until the following structure was prepared:



This structure constitutes the core of the Lp(a) peptide construct.

20

EXAMPLE 2

SYNTHESIS OF A LIPOPROTEIN(a) PEPTIDE ONTO THE CORE CONSTRUCT

For synthesis of the lipoprotein(a) peptide onto the core construct, α -amino-Boc-protected amino acids were

25 used exclusively. Other protecting groups used were p-methoxybenzyl protection on L-cysteine, O-benzyl on L-serine, ϵ -carbobenzoxyl on L-lysine and a Γ -benzyl ester on L-glutamic acid.

The general coupling reaction used involved preparing a symmetrical anhydride of the requisite amino acid by dissolving 0.4 millimole of the Boc-protected amino acid in 3-5 ml of dichloromethane and cooling the resultant solution to 4°C. To this was added 2 millimoles of dicyclohexylcarbodiimide dissolved in 10 ml of dichloromethane and the reagents were allowed to react for 1 hour at 4°C. The solution was then warmed to 22°C and filtered onto the resin which had previously been equilibrated in dichloromethane. The resin was then rocked with the anhydride solution for 1-2 hours at 22°C. A sample of the resin was then removed and the completeness of the reaction determined by ninhydrin analysis. If the reaction was found to be less than 95% complete, a second coupling was performed using the identical procedure substituting dimethylformamide for dichloromethane.

For coupling N-t-Boc-L-glycine, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide was substituted for dicyclohexylcarbodiimide. For coupling N-t-Boc-L-glutamic acid γ -benzyl ester, 0.4 millimole of the amino acid was dissolved in 5 ml dichloromethane and then added to the resin which was then rocked for 5 minutes at 22°C. To this was then added 2 millimoles of dicyclohexylcarbodiimide dissolved in 7 ml dichloromethane and the resin was rocked for 18 hours at 22°C to provide an acceptable degree of coupling.

Following each successful coupling step the Boc

protective group was removed by rocking the resin for 30 minutes in 15 ml of trifluoroacetic acid : dichloromethane (1:1) solution containing 1mg/ml indole, rinsing the resin with 6 changes of 15 ml
5 dichloromethane, neutralizing the resin for 20 minutes with 2 changes of 15 ml of a 5% solution of diisopropylethylamine in dichloromethane and rinsing the resin with 3 changes of 20 ml dichloromethane.

The structure of the core construct with the
10 synthesized peptide was as follows:

RESIN-PAM-CH₂O-βAla-KK₂K₄-(GGGAVCGGVISGPCKKPE-NH₂)₈.

A quantitative ninhydrin assay performed in duplicate on the completed structure indicated free amine contents of 0.087 and 0.103 millimole per gram versus an
15 anticipated 0.08 millimole per gram by prior analysis on the unreacted resin.

The peptide construct was then acylated to neutralize the charge on the N-terminal amino group. A solution was prepared consisting of 3 mM acetic anhydride in
20 dimethylformamide with 3 millimoles of 4-dimethylaminopyridine. The resin containing the peptide construct was rocked with 15 ml of this reagent for 30 minutes at 22°C. The resin was then washed with dimethylformamide. A resin sample assayed using the
25 ninhydrin procedure indicated the absence of free amino residues on the peptide construct.

EXAMPLE 3

**CLEAVAGE OF THE CONSTRUCT FROM THE RESIN
AND PREPARATION FOR IMMUNIZATION**

The resin containing the peptide construct was treated with 20 ml of a trifluoromethanesulfonic acid : trifluoroacetic acid : dimethylsulfide : m-cresol solution (1:5:3:1 v/v) for 4 hours at 0°C. Thirty milliliters of a 1% solution of β -mercaptoethanol in anhydrous ether cooled to -5°C was then added and thoroughly mixed with the reaction mixture. The mixture was then transferred to a 250 ml separation flask and the construct was extracted by shaking the reaction solution with 100 ml of 0.1M tris buffer, pH 8.0 containing 8M urea and 0.2M dithiothreitol. The layers were allowed to separate and the aqueous layer was placed in Spectra por dialysis tubing (1000 M_r cutoff) and dialyzed successively overnight against 0.1M ammonium carbonate buffer, pH 8.0 with 0.1M β -mercaptoethanol and 8M urea; 0.1M ammonium carbonate buffer, pH 8.0 with 8M urea; 0.1M ammonium carbonate buffer, pH 8.0 with 2M urea; water; and 1M acetic acid.

The material (in 1M acetic acid) was then lyophilized, the recovered material analyzed for amino acid content and used without further purification. The result of the amino acid analysis was as follows:

<u>Amino Acid</u>	<u>Ratio Expected</u>	<u>Ratio Found</u>
E	8	8.34
S	8	8.64
G	48	58.90
A+ β A	9	11.30

	P	16	16.90
	V	16	16.20
	C	16	PRESENT
	I	8	5.80
5	K	23	25.90

EXAMPLE 4

IMMUNIZATION OF MICE WITH THE PEPTIDE CONSTRUCT

Adult BALB/C mice were injected with the peptide construct as prepared in Example 3. Each mouse received
10 50 micrograms of the lyophilized peptide dissolved in 1 ml of complete Freund's adjuvant (administered 0.5 ml intraperitoneally and 0.5 ml subcutaneously). Serum was collected from one eye of each mouse 30 days after peptide injection and tested for antibodies to the
15 peptide construct by a microplate EIA (enzyme immunoassay) as described in Example 6 and for antibodies to lipoprotein(a) by an Ouchterlony immunoprecipitation assay as described in Example 9. Mice which tested
20 positive for antibodies against the peptide construct by microplate EIA were reinoculated 4 days prior to cell fusion by injection of 50 micrograms of the peptide construct into the tail vein (in PBS, 0.2 ml per mouse).

EXAMPLE 5

25 PRODUCTION OF HYBRIDOMAS BY FUSION OF IMMUNE MOUSE SPLEEN CELLS WITH MOUSE MYELOMA CELLS

Mouse myeloma cells (SP2/0-Ag-14) were grown from frozen seed stock previously passaged in Opti-MEM^R (Gibco

#320-1985) containing 8-azaguanine. Th cells were thawed and grown in Optimem media (Opti-MEM^R with 0.1% β -mercaptoethanol, 1mM L-glutamine, 1mcg/ml Fungizone, 0.05 mg/ml gentamicin sulfate and 6% FBS (fetal bovine serum))
5 for 2 days prior to fusion. The cells were then collected by centrifugation and washed in cold (4°C) Optimem media without FBS. A cell sample was removed and viability was checked by trypan blue exclusion (95+% viability). The cells were then centrifuged and
10 resuspended in cold Optimem media without FBS two more times and finally resuspended in cold Optimem media without FBS.

The mice from Example 4 which tested positive for antibodies to the peptide construct were sacrificed by
15 cervical dislocation. The spleens were removed under aseptic conditions, washed with cold Optimem media without FBS, placed into a mesh grinding cup over a conical tube on ice and minced with scissors. The cells were forced through the mesh with a glass rod and rinsed
20 into the tube with ACK buffer (7mM carbonate buffer, pH 7.4 with 0.15M ammonium chloride and 0.01M EDTA (ethylenediamine tetraacetic acid)). The cells were allowed to stand for 10 minutes, pelleted by centrifugation and resuspended in 50 ml of cold Optimem
25 without FBS. Clotted material was removed with a 10 ml pipette. An aliquot of cells was removed, diluted 1:10 with Optimem and the number of viable spleen cells determined by trypan blue exclusion. The spleen cells

were then mixed in a round-bottomed tube with SP2/0 cells to achieve a ratio of 3:1.

The cells were pelleted by centrifugation and the supernatant was poured off. The tube was then placed
5 into a 37°C water bath and gently tapped until the cell pellet formed a smooth slurry. To this was then added 2 ml of 37°C polyethylene glycol (mw 1,500) slowly over a 1 minute period with gentle agitation to mix the solution with the slurry. The cells were then pelleted by
10 centrifugation and 2 ml of 37°C Optimem media without FBS was slowly added over 1 minute followed by the addition of 10 ml more of the same solution over the next two minutes. The cells and solution were transferred to a 50 ml conical tube and an additional 10 ml of 37°C serumless
15 Optimem media was added slowly. The cells were then pelleted and resuspended in 25 ml of 2X HAT medium (4% solution of 50X HAT (B. Mannheim) in Optimem media containing 15% MRC-5 conditioned EMEM/NEAA medium). The cells were then diluted into 100-150 ml of 2X HAT medium
20 and dispensed into 96 well polystyrene microplates at 0.1 ml per well. The microplates were then placed into a water-jacketed CO₂ incubator at 37°C and 5% CO₂. On days 4, 7 and 10 post fusion the medium was changed with 1X HAT (2% solution of 50X HAT in Optimem media containing
25 15% MRC-5 conditioned EMEM/NEAA medium) using 0.1 ml per well.

When visible colonies appeared, all of the wells were tested for production of antibodies to the peptide

construct by the enzyme immunoassay described below in Example 6. Those cells showing elevated activity in the enzyme immunoassay were subcloned twice and grown out to eliminate non-producing cells. After 2 subclones the cells were tested for production of antibodies to the lipoprotein(a) (Example 7) by the enzyme immunoassay described below in Example 8.

EXAMPLE 6

10 ENZYME IMMUNOASSAY TO DETECT ANTIBODIES TO THE APOLIPOPROTEIN(a) PEPTIDE CONSTRUCT

For this assay, peptide construct dissolved in 0.1M sodium carbonate buffer, pH 9.0 was incubated for 18 hours at 37°C in a polystyrene 96 well microplate (0.5 microgram peptide construct per 0.12 ml per well). The plate was then washed 3 times with wash buffer (5% lactose solution containing 0.5% BSA (bovine serum albumin) and 0.1% sodium azide). The plates were then stored at 4°C with 0.2 ml of wash buffer in each well until required for an assay. Prior to an assay the wash buffer was removed and the plates dried by inverting them and tapping them on a paper towel until no droplets were observed inside the wells.

Sera to be assayed (from mice immunized with peptide construct in Example 4) was diluted 1:50 with sample dilution buffer (phosphate buffered saline (PBS), pH 7.0 containing 1% BSA, 0.1% sodium azide and 0.1 Triton X-705) and 0.12 ml aliquots of the diluted samples were added to wells in the assay plate. The plate was covered

and warmed to 37°C for 1 hour. The plate was then wash d
with assay wash buffer (0.3M TRIS buffer, pH 8.0 with
1.2M ammonium sulfate, 0.12M magnesium chloride, 0.001M
zinc chloride, 0.1% sodium azide and 0.001% Triton X-
5 705), drained and tapped dry.

To each well was then added 0.1 ml of alkaline
phosphatase labeled goat anti-mouse IgG diluted 1:500 with
PBS. The plate was then incubated for 1 hour at 37°C,
washed four times with assay wash buffer, drained and
10 tapped dry. The presence of alkaline phosphatase
activity was determined by the addition of 0.1 ml of
substrate solution (p-nitrophenylphosphate in
diethanolamine buffer; Kirkegaard & Perry Laboratories,
Inc., Gaithersburg, MD) to each well followed by
15 incubation at room temperature for 30 minutes. When the
most reactive well achieved an absorbance of 1.5-2.0 at
410 nm the reaction in all wells was stopped by the
addition of 0.1 ml 5% EDTA. The absorbance at 410 nm of
each well was determined and recorded using a Dynatech
20 MR-300 ELISA plate reader. A sample was deemed positive
if the OD₄₁₀ was greater than 0.05 absorbance units when
compared to the absorbance of a well containing no
peptide construct coating.

EXAMPLE 7

25 ISOLATION AND PURIFICATION OF LIPOPROTEIN(a) FROM HUMAN SERUM

A plasma sample was obtained from a single donor who
had tested positive for the presence of lipoprotein(a) by

th enzyme immunoassay described in Example 10. Sixty-five ml of the sample was centrifuged at 105,000 xg for 24 hours at 10°C. The floating layer was removed and the infranatant solution was brought back to a total volume
5 of 65 ml with deionized water. To this solution was then added 0.715 ml of a 100 mg per ml solution of high molecular weight dextran sulfate (mw 500,000) and 7.15 ml of 1M calcium chloride. The solution was allowed to precipitate for 1 hour at 4°C. The solids were removed
10 by centrifugation at 1,600 xg for 15 minutes at 10°C. The upper solution was poured off and the solids were allowed to dissolve overnight in 60 ml of a sodium chloride solution (1.12 kg/L density at 10°C) containing 0.1mM EDTA and 0.1mM PMSF (phenylmethylsulfonylfluoride).
15 The solution was then centrifuged at 105,000 xg for 23 hours at 10°C. The upper layer was removed, placed in Spectra por 7 dialysis tubing (M_r 8,000 cutoff) and dialyzed against a sodium chloride solution (1.05 kg/L density at 10°C) containing 0.1mM EDTA and 0.1mM PMSF for
20 48 hours and 2 changes of dialysis fluid at 10°C. The dialysate was then centrifuged at 105,000 xg for 72 hours at 10°C. The floating material was removed and the infranatant solution, containing the lipoprotein(a), was stored at 4° for further use.

25

EXAMPLE 8**ENZYME IMMUNOASSAY TO DETECT
ANTIBODIES TO NATIVE LIPOPROTEIN(a)**

For this assay, isolated Lp(a) from Example 7 was

diluted 1:256 with 0.1M sodium carbonate buffer, pH 9.0. This solution was then placed into a 96 well polystyrene microplate (0.3 microgram protein per 0.12 ml per well) and incubated for 18 hours at 37°C. The plate was then
5 washed 4 times with wash buffer (5% lactose solution with 0.5% BSA and 0.1% sodium azide). The plates were then stored at 4°C with 0.2 ml of wash buffer in each well until required for an assay. Prior to an assay the wash buffer was removed and the plates dried by inverting them
10 and tapping them on a paper towel until no droplets were observed inside the wells.

Sera to be assayed were diluted 1:50 with sample dilution buffer (PBS, pH 7.0 containing 1% BSA, 0.1% sodium azide and 0.1% Triton X-705) and 0.12 ml aliquots
15 of the diluted samples were added to the wells in the assay plate. The plate was covered and warmed to 37°C for 2 hours. The plate was then washed with assay wash buffer (0.3M TRIS buffer, pH 8.0 with 1.2M ammonium sulfate, 0.12M magnesium chloride, 0.001M zinc chloride,
20 0.1% sodium azide and 0.001% Triton X-705), drained and tapped dry.

To each well was then added 0.1 ml of alkaline phosphatase-labeled goat anti-mouse IgG diluted 1:500 with PBS. The plate was then incubated for 1 hour at
25 37°C, washed four times with assay wash buffer, drained and tapped dry. The presence of alkaline phosphatase activity was determined by the addition of 0.1 ml of substrate solution (p-nitrophenylphosphate in

diethanolamine buffer; Kirkgaard & Perry Laboratories, Inc., Gaithersburg, MD) to each well followed by incubation at room temperature for 30 minutes. When the most reactive well achieved an absorbance of 1.5-2.0 at 410 nm the reaction in all wells was stopped by the addition of 0.1 ml 5% EDTA. The absorbance at 410nm of each well was determined and recorded using a Dynatech MR-300 ELISA plate reader. A sample was deemed positive if the OD₄₁₀ was greater than 0.05 absorbance units when compared to the absorbance of a well containing no native lipoprotein(a) coating.

EXAMPLE 9

ROUCHTERLONY IMMUNODIFFUSION ASSAY

A solution of 1% agarose with 1 mM magnesium and 1 mM calcium is heated to boiling and 2-3 ml is placed onto a microscope slide and allowed to solidify. Upon solidification, holes (3 mm diameter) are punched into the agarose gel using the tip of a Pasteur pipette in a rosette pattern consisting of a central well with eight wells surrounding it at a distance of 5 mm. Purified lipoprotein(a) as prepared in Example 7 in a total volume of 10-15 microliters was placed into the central well. The surrounding wells were filled with 10-15 microliters of sera or culture fluid to be tested for antibodies to lipoprotein(a). The slide was then incubated for 16-24 hours at 37°C in a 100% humidity chamber. At the end of the incubation time the slide was inspected for the

presence of white precipitation lines or areas indicative of antibody:antigen interactions.

EXAMPLE 10

ENZYME IMMUNOASSAY TO DETECT LIPOPROTEIN(a)

5 For this assay, antibody directed against the peptide construct (Example 5) was diluted in 20mM Citrate buffer, pH 6.0 and incubated for 18 hours at 37°C in a polystyrene 96 well microplate (0.6 microgram antibody per 0.12 ml per well). The plate was then washed 3 times
10 with wash buffer (5% lactose solution containing 0.5% BSA (bovine serum albumin) and 0.1% sodium azide). The plates were then stored at 4°C with 0.2 ml of wash buffer in each well until required for an assay. Prior to an assay the wash buffer was removed and the plates dried by
15 inverting them and tapping them on a paper towel until no droplets were observed inside the wells.

Sera to be assayed were diluted 1:50 with sample dilution buffer (phosphate buffered saline (PBS), pH 7.0 containing 1% BSA, 0.1% sodium azide and 0.1% Triton X-
20 705) and 0.12 ml aliquots of the diluted samples were added to wells in the assay plate. The plate was covered and warmed to 37°C for 1 hour. The plate was then washed with assay wash buffer (0.3M TRIS buffer, pH 8.0 with 1.2M ammonium sulfate, 0.12M magnesium chloride, 0.001M
25 zinc chloride, 0.1% sodium azide and 0.001% Triton X-705), drained and tapped dry.

To each well was then added 0.1 ml of alkaline

phosphatase-labeled sheep anti-human apolipoprotein B-100 IgG diluted 1:1000 with sample dilution buffer. The plate was then incubated for 1 hour at 37°C, washed four times with assay wash buffer, drained and tapped dry.

5 The presence of alkaline phosphatase activity was determined by the addition of 0.1 ml of substrate solution (p-nitrophenylphosphate in diethanolamine buffer; Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD) to each well followed by incubation at

10 room temperature for 30 minutes. When the most reactive well achieved an absorbance of 1.5-2.0 at 410 nm the reaction in all wells was stopped by the addition of 0.1 ml 5% EDTA. The absorbance at 410 nm of each well was determined and recorded using a Dynatech MR-300 ELISA


15 plate reader. A sample was deemed positive if the OD₄₁₀ was greater than 0.05 absorbance units when compared to the absorbance of a well containing no antibody coating.

EXAMPLE 11

PREPARATION OF A SYNTHETIC STANDARD

20 To circumvent the difficulties associated with the preparation of a standard solution of purified, stabilized native lipoprotein(a), the synthesis of a synthetic secondary standard for use in enzyme immunoassays of lipoprotein(a) and apolipoprotein(a) is

25 proposed. An exemplary structure for a synthetic standard for lipoprotein-(a) would be as follows:



where X = protease cleavage region of apolipoprotein(a)

Y = C-terminal end of apolipoprotein B-100

Z = spacer region to separate epitopes

An exemplary structure for an apolipoprotein(a) secondary

5 standard would be as follows:

AcO-VEPKKCPGSIVGGCVALTP (G)₂₀ VVQDCYHGDGQ-COOH

where X = protease cleavage region of apolipoprotein(a)

Y = C-terminal end of apolipoprotein(a)

Z = spacer region to separate epitopes

10 While these exemplary secondary standards are designed to interact, respectively, with antibodies directed against the C-terminal regions of apolipoprotein B-100 and apolipoprotein(a) as the second (reporter) antibody in the assay format, other regions of the

15 proteins can be synthesized to provide unique epitopes which can also be used. The glycine spacer region can be altered both in length and in amino acid composition to provide an optimized peptide which will be water soluble and be of sufficient length to negate any steric

20 hindrance between the antibody bound to the solid surface (the capture antibody) and the labelled antibody used to provide the signal which can be related to the quantity of native material bound to the solid support (the reporter antibody).

25 One advantage of these secondary standards is that

th aspects of th immunological int ractions which allow
the assay to function can be supplied synthetically to
provide a model which can reproduce the signal generated
by a known amount of target antigen interacting within
5 the system. By determining the signal produced by a
(weighed) secondary standard, a relationship can be made
to the signal produced by the natural material in the
assay, thereby allowing a quantitative determination of
the native material.

10 It will be apparent to those skilled in the art
that various modifications and variations can be made to
the compositions of matter and methods of this invention.
Thus, it is intended that the present invention cover the
modifications and variations of this invention provided
15 they come within the scope of the appended claims and
their equivalents.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: CHIKNAS, Steven G.

5 (ii) TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC
COMPOSITONS AND METHODS FOR
LIPOPROTEIN(a)

(iii) NUMBER OF SEQUENCES: 1

(iv) CORRESPONDENCE ADDRESS:

10 (A) ADDRESSEE: Foley & Lardner, Schwartz,
Jeffery,

Schwaab

(B) STREET: 1800 Diagonal Road, Suite 500

(C) CITY: Alexandria

15 (D) STATE: VA

(E) COUNTRY: USA

(F) ZIP: 22313-0299

(v) COMPUTER READABLE FORM:

20 (A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: PatentIn Release #1.24

(vi) CURRENT APPLICATION DATA:

25 (A) APPLICATION NUMBER:

(B) FILING DATE:

(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

30 (A) NAME: Sandercock, Colin G.

(B) REGISTRATION NUMBER: 31,298

(C) REFERENCE/DOCKET NUMBER: 32879/102

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (703)836-9300

(B) TELEFAX: (703)683-4109

(C) TELEX: 899149

35 (2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: N

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(x) PUBLICATION INFORMATION:

- 5 Kohr, W. (A) AUTHOR: Eaton, D. L., Fless, G. M.,
Miller, J., McLean, J. W. Xu, Q.-T.,
M. C. G., Lawn, R. M., Scanlu, A.
- 10 (B) TITLE: Partial amino acid sequence of
is apolipoprotein(a) shows that it
homologous to plasminogen
- 15 (C) JOURNAL: Proc. Natl. Acad. USA
(D) VOLUME: 84
(E) ISSUE:
(F) PAGES: 3224-3228
(G) DATE: MAY-1987

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

20 Val Ala Glu Pro Lys Lys Cys Pro Gly Ser Ile Val Gly Gly Cys
1 5 10
15

What Is Claimed Is:

1. A peptide that presents an epitope which is substantially similar to an epitope of the activation site region of apolipoprotein(a), wherein antibodies that bind to said peptide also bind to said epitope of said activation site region.
2. A peptide according to claim 1, wherein said peptide comprises a serine-isoleucine (SER-ILE) sequence or its immunological equivalent.
3. A peptide in accordance with claim 2, further comprising adjacent to said a serine-isoleucine (SER-ILE) sequence or its immunological equivalent, amino acid residues from the apolipoprotein(a) activation site region sequence.
4. A peptide according to claim 3, comprising the following sequence of amino acid residues or its immunological equivalent:
GLU-PRO-LYS-LYS-CYS-PRO-GLY-SER-ILE-VAL-GLY-GLY-CYS-VAL-ALA.
5. A peptide according to claim 1, wherein antibodies that bind to said peptide also bind to said pitope of said activation site region but substantially do not bind to plasminogen.

6. An peptide construct comprising a carrier onto which is bound a peptide according to claim 5.

7. An peptide construct comprising a carrier onto which is bound a peptide according to claims 1.

8. A construct in accordance with claim 7, wherein the carrier is a core comprising a plurality of lysine residues, and said peptide is bound to said core at the carboxyl end of said peptide.

9. A construct in accordance with claim 8, wherein said core comprises a plurality of eight lysine residues.

10. A construct according to claim 9, wherein the construct has a core of the following structure:

Resin-PAM-CH₂O-βAla-K-K₂-K₄-(GGG-NH₂)₈.

11. A construct according to claim 10, wherein the construct has the following structure:

βAla-Lys-(Lys₂)-(Lys₄)-((Gly₃)-Ala-Val-Cys-Gly-Gly-Val-Ile-Ser-Gly-Pro-Cys-Lys-Lys-Pro-Glu-OAc)₈.

12. A process for preparing an antibody which binds to the activation site region of apolipoprotein(a), said process comprising the steps of immunizing an animal or mammal with a construct according to claim 7.

13. A process for preparing an antibody which binds to the activation site region of apolipoprotein(a), but which substantially does not bind plasminogen, said process comprising the steps of immunizing an animal or mammal with a construct according to claim 6.

14. An antibody produced by the process of claim 12.

15. An antibody produced by the process of claim 13.

16. An antibody which binds to the activation site region of lipoprotein(a).

17. A quantity of antibody consisting essentially of antibody according to claim 16.

18. An antibody according to claim 16, which recognizes an epitope presented by a peptide comprising the amino acid residue sequence SER-ILE or its immunological equivalent.

19. An antibody according to claim 18, which recognizes an epitope presented by a peptide comprising the following amino acid residue sequence or its immunological equivalent:

GLU-PRO-LYS-LYS-CYS-PRO-GLY-SER-ILE-VAL-GLY-GLY-CYS-VAL-ALA.

20. Polyclonal serum containing an antibody according to claim 18.

21. An antibody according to claims 18 which is a monoclonal antibody.

22. A hybridoma which produces a monoclonal antibody according to claim 21.

23. An antibody according to claim 18 which substantially does not bind to plasminogen.

24. Polyclonal serum containing an antibody according to claim 23.

25. An antibody according to claim 23 which is a monoclonal antibody.

26. A quantity of antibody consisting essentially of antibody according to claim 23.

27. A hybridoma which produces a monoclonal antibody according to claim 25.

28. An assay for determining the presence of lipoprotein(a) in a sample comprising the steps of:

A. contacting the sample with a first antibody which binds to an epitope presented by the activation

site region of apolipoprotein(a),

B. maintaining the first antibody in contact with the sample for a time sufficient to form an apolipoprotein(a)-first antibody reaction product, and

C. determining whether any apolipoprotein(a)-first antibody reaction product is present.

29. An assay according to claim 28, wherein said assay is in a sandwich assay format.

30. An assay according to claim 28, wherein said assay is in a precipitation assay format.

31. An assay according to claim 28, wherein said assay is in a homogeneous assay format.

32. An assay according to claim 29, wherein the Step C is carried out using a second antibody which binds to an epitope which is not present on the activation site region of apolipoprotein(a).

33. An assay according to claim 32, wherein the second antibody is an anti-B-100 antibody.

34. An assay according to claim 32, wherein the second antibody is an anti-plasminogen antibody.

35. An assay according to claim 32, wherein the

second antibody is an anti-apolipoprotein(a) antibody.

36. An assay according to claim 28, wherein the first antibody recognizes an epitope presented by a peptide comprising the amino acid residue sequence SER-ILE or its immunological equivalent.

37. An assay according to claim 28, wherein the first antibody recognizes an epitope presented by a peptide comprising the following amino acid residue sequence or its immunological equivalent:
GLU-PRO-LYS-LYS-CYS-PRO-GLY-SER-ILE-VAL-GLY-GLY-CYS-VAL-ALA.

38. An assay according to claim 28, wherein the first antibody is a monoclonal antibody.

39. An assay according to claims 28, wherein the first antibody is contained in polyclonal serum.

40. An assay according to claim 28, wherein said first antibody substantially does not bind to plasminogen.

41. An assay according to claim 28, wherein said assay comprises the step of adding a protease to cleave any plasminogen present in the sample.

42. An assay according to claim 41, wherein said first antibody substantially does not bind to plasminogen.

43. An assay for lipoprotein in a sample, wherein the improvement comprises the use of an antibody which binds to an epitope presented by the activation site region of apolipoprotein(a).

44. An assay according to claim 43, wherein said antibody recognizes an epitope presented by a peptide comprising the amino acid residue sequence SER-ILE or its immunological equivalent.

45. An assay according to claim 43, wherein said antibody recognizes an epitope presented by a peptide comprising the following amino acid residue sequence or its immunological equivalent:
-GLU-PRO-LYS-LYS-CYS-PRO-GLY-SER-ILE-VAL-GLY-GLY-CYS-VAL-ALA-.

46. An assay according to claim 43, wherein said antibody substantially does not bind to plasminogen.

47. A diagnostic system, in kit form, comprising, in an amount sufficient to perform at least one assay, of an antibody according to claims 16.

48. A method of chromatographically separating

lipoprotein(a) or apolipoprotein(a) from a sample comprising the steps of:

A. contacting the sample with an antibody according to claim 16 to form a lipoprotein(a)- or apolipoprotein(a)-antibody reaction product, and

B. separating the reaction product formed in Step A from the remainder of the sample.

49. A method according to claim 48, wherein said antibody is a monoclonal antibody.

50. Chromatographic material comprising an antibody according to claims 16, which is bound to a carrier.

51. Chromatographic material according to claim 50, wherein the antibody is a monoclonal antibody.

52. A therapeutic conjugate comprising an antibody according to claims 16.

53. A therapeutic conjugate according to claim 52, wherein said antibody is conjugated to an agent which alters lipoprotein(a).

54. A therapeutic conjugate according to claim 53, wherein said agent is a toxin.

55. A therapeutic conjugate according to claim 52,

wherein the antibody is a monoclonal antibody.

56. A pharmaceutical composition comprising a conjugate according to claim 52 together with a pharmaceutically acceptable carrier.

57. A pharmaceutical composition comprising an antibody according to claim 16 together with a pharmaceutically acceptable carrier.

58. A method of reducing the presence of lipoprotein(a) in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of the pharmaceutical composition of claim 56.

59. A method of reducing the presence of lipoprotein(a) in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of the pharmaceutical composition of claim 57.

60. A method of provoking an immune response against apolipoprotein(a) comprising administering to a mammal an amount of a peptide construct according to claim 6 sufficient to provoke said response.

61. A synthetic secondary standard peptide

comprising first and second regions separated by a linkage region, wherein

said first region comprises amino acid residues in a sequence which will bind a first antibody, and said second region comprises amino acid residues which will bind a second antibody, and

said linkage region is comprised of a material to which said first and second antibodies will not bind, and is of sufficient length to minimize steric hindrance in the binding of said first and second antibodies to said first and second regions.


62. A synthetic secondary standard according to claim 61, wherein one of the regions binds antibodies which recognize an epitope of the N-terminal or C-terminal region of apolipoprotein(a) or apolipoprotein B-100.

63. A synthetic secondary standard according to claim 61, wherein one of the regions binds antibodies which recognize an epitope of the activation site region of apolipoprotein(a).

64. A synthetic secondary standard according to claim 62, wherein one of the regions binds antibodies which recognize an epitope of the activation site region of apolipoprotein(a).


1 / 1

FIG. I



INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/08654

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ³		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC (5) : G01N 33/543, 33/53; A61K 37/02, 39/00		
US CL : 435/7.94; 436/518; 424/85.8; 530/326		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁴		
Classification System	Classification Symbols	
U.S.	Please See Attached Sheet.	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched ⁵		
APS; SWISS PROT., STN		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹⁴		
Category*	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸
A,P	US, A, 5,034,332 (Rapacz et al.) 23 July 1991, see entire document.	12-47
Y	US, A, 4,970,144 (Fareed et al.) 13 November 1990, see entire document.	1-55, 53-56
Y	US, A, 4,698,298 (Dedieu et al.) 06 October 1987, see entire document.	1-55,53-56
A	US, A, 4,883,765 (Tamir et al.) 28 November 1989.	48-51
Y	US, A, 4,877,746 (Jansson et al.) 31 October 1989, see entire document.	1-55,53-56
Y	US, A, 4,677,057 (Curtiss et al.) 30 June 1987, see entire document.	1-51,53-56
Y	US,A, 4,945,040 (Fless et al) 31 July 1990, see entire document.	1-51,53-56
Y	US, A, 5,087,572 (Castellino et al.) see abstract only.	1-11
<p>* Special categories of cited documents:¹⁵</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search ²		Date of Mailing of this International Search Report ²
03 MARCH 1992		30 MAR 1992
International Searching Authority ¹		Signature of Authorized Officer ²⁰
ISA/US		Arti Shah 

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

Y	J. Lipid Res., Vol. 31, No. 3, issued 1990, Marfiovina et al. "immunochemical characterization of six monoclonal antibodies to human apolipoprotein A-I: epitope mapping and expression", see Abstract No. 196338F vol. 112(21).	12-47
Y	Eur. J. Biochem., Vol. 175, No. 1, issued 1988, Chen et al., "Primary sequence mapping of human apolipoprotein B-100 epitopes. Comparisons of trypsin accessibility and immunoreactivity and implication for apoB conformation", see Abstract no. 144839x, Vol. 109(17).	1-47

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers , because they relate to subject matter (1) not required to be searched by this Authority, namely:

2. ☐ Claim numbers , because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out (1), specifically:

3. ☐ Claim numbers , because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING²

This international Searching Authority found multiple inventions in this international application as follows:

See Attachment.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
(Telephone Practice)
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Search Authority did not invite payment of any additional fee.

Remark on protest

- ☐ The additional search fees were accompanied by applicant's protest.
☐ No protest accompanied the payment of additional search fees.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category ¹⁶	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸
A	Arteriosclerosis (Dallas), Vol. 7, No. 2, issued 1987, Marcel et al., "Mapping of human apolipoprotein B antigenic determinants", see Abstract No. 898414, Vol. 108(11).	1-47
Y	Biochemistry, Vo. 26, No. 18, issued 1987, Silberman et al., "Monoclonal antibodies as probes of high-density lipoprotein structure: identification and localization of a lipid-dependent epitope", see Abstract No. 132246x, Vol. 107(15).	12-56
P,Y	Biochemistry, Vol. 30, No. 27, issued 1991, Simon et al., "Tissue-Type Plasminogen Activator Binds to an is inhibited by Surface-Bound Lipoprotein(a) and Low-Density Lipoprotein", pages 6671-6677, see entire document.	1-56
T	J. Biological Chem., Vol. 266, No. 35, issued 15 December 1991, Banka et al., "Localization of an Apolipoprotein A-I Epitope critical for Activation of Lecithin-Cholesterol Acyltransferase", pages 23886-23892, see entire document.	12-58, 52
Y	Proc. Natl. Acad. Sci. USA, Vol. 84, issued May 1987, Eaton et al., "Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen", pages 3224-3228, see entire document.	1-56
Y	Proc. Natl. Acad. Sci. USA, Vol. 85, issued August 1988, Tam et al., "Synthetic peptide vaccine design: Synthesis and properties of high density multiple antigenic peptide system", pages 5409-5413, see entire document.	1-11
Y	Nature, Vol. 330, issued 12 November 1987, McLean et al., "cDNA sequence of human apolipoprotein(a) is homologous to plasminogen", pages 132-137, see entire document.	1-11
Y	J. Biological Chemistry, Vol. 264, No. 10, issued 05 April 1989, Tomlison et al., "Rhesus Monkey Apolipoprotein(a)", pages 5957-5965, see entire document.	1-11

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category ^a	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸
Y	J. Biological Chemistry, Vol. 252, No. 19, issued 10 October 1977, Schonfeld et al., "Antigenic properties of Apoproteins A-I and A-II in intact high density Lipoprotein", pages 6651-6654, see entire document.	1-56
Y	J. Biological Chemistry, Vol. 252, No. 19 issued 10 October 1977, Schonfeld et al., "Use of Antibody specificity to study the surface disposition of Apoproteins A-I on Human High Density Lipoproteins", pages 6655-6659, see entire document.	1-56
Y	EMBO, Vol. 8, No. 13, issued 1989, Salonen et al., "Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it", pages 4035-4040, see entire document.	1-56